Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

This study is an open-label, international, multi-center, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene fusion.

本研究为一项开放标签、国际多中心II期临床试验，受试对象为携带NRG1基因融合的复发、局部晚期或转移性实体瘤成年患者。